RBC Just Initiated Coverage of GE HealthCare. Here’s Why It Matters.

The call came in at 8:17 a.m., and by 9:30, the market had already made up its mind. RBC Capital Markets lit the fuse on GE HealthCare Technologies Inc. (GEHC) with an “Outperform” rating and a price target of $98 — and traders wasted no time pushing the stock up nearly 2% at the open. For a company that’s spent the last fifteen months quietly proving it can stand on its own after the GE spin-off, this is a big moment.

RBC isn’t just slapping a rating on a stock. They’re making a bet on the future of medical imaging, AI-driven diagnostics, and the $500 billion med-tech market. And they’re telling clients: get in now, because the next decade is going to look very different.

What RBC Sees That Others Might Be Missing

Analysts at RBC led by Shagun Singh published the initiation note on Tuesday, calling GEHC a “top pick in large-cap med-tech” and highlighting its 40% exposure to high-growth imaging segments like MRI, CT, and ultrasound. The firm also pointed to the company’s AI-enabled software portfolio — tools that help radiologists detect cancers, strokes, and fractures faster — as a key differentiator.

Here’s the thing: GE HealthCare isn’t some scrappy startup. It’s a $38 billion behemoth with 50,000 employees and a century of history inside the GE umbrella. But post-spin-off, it’s leaner and more focused. In the first quarter of 2024, the company reported $4.65 billion in revenue, beating analyst expectations by 2.3%. Organic order growth hit 5%, and margins are creeping up.

“GE HealthCare is entering a sweet spot where demographic tailwinds — aging populations in the U.S., Europe, and Japan — collide with technological leaps in AI and digital health,” said Dr. Emily Tran, a healthcare equity analyst at Summit Wealth Partners. “RBC’s initiation is a signal that institutional investors are ready to treat this stock as a core holding, not just a spin-off story.”

And it’s not just about imaging. The company’s Patient Care Solutions division, which covers monitoring and anesthesia equipment, grew 7% year-over-year in Q1. Meanwhile, its Pharmaceutical Diagnostics unit — think contrast agents for scans — posted 11% growth. That diversification gives RBC confidence that GEHC can weather a slower hospital spending cycle.

The MedTech Macro Moment — Why Now?

MedTech has been a bit of a wallflower in this bull market. While everyone piled into AI stocks like NVDA (still a billionaire favorite, by the way), healthcare equipment companies traded sideways. But that’s starting to shift.

Hospital capital budgets are finally loosening after years of pandemic-era belt-tightening. The American Hospital Association projected capital spending growth of 3-5% annually through 2026. And with the FDA approving new AI algorithms for medical imaging at a rate of one every three days in 2023, the upgrade cycle is accelerating.

GE HealthCare is sitting on a pile of cash — $2.1 billion at the end of Q1 — and management has signaled it’s hunting for bolt-on acquisitions in digital health and molecular imaging. That could be the catalyst that pushes the stock past RBC’s $98 target.

“The med-tech playbook right now is all about recurring revenue from software and services,” said James Harrington, a medical devices analyst at Tower Bridge Research. “GEHC’s installed base of over 4 million imaging systems is a goldmine for service contracts and AI upgrades. That’s the kind of stickiness that justifies a premium multiple.”

The company’s Edison AI platform — think of it as an operating system for hospital imaging — already has 80+ FDA-cleared applications. That’s a moat that smaller competitors can’t easily replicate.

Valuation: Not Cheap, But Fair

Let’s talk numbers. At $86.50 (as of Tuesday’s close), GEHC trades at 20.5x forward earnings. That’s a slight premium to the S&P 500’s 18x, but a discount to pure-play med-tech peers like Stryker (24x) and Boston Scientific (22x). RBC’s $98 target implies roughly 13% upside — not eye-popping, but steady.

The bigger story is margin expansion. GEHC’s adjusted operating margin came in at 17.3% in Q1, up 150 basis points year-over-year. Management sees room to hit 18-20% by 2026 through supply-chain optimization and higher-margin software sales. If they deliver, the stock could re-rate higher.

But — and there’s always a but — China is a wildcard. GE HealthCare generates about 15% of revenue from China, and the government’s anti-corruption campaign in healthcare has slowed hospital purchasing. The company flagged “uncertainty” in its 10-Q. RBC acknowledges the risk but believes it’s already baked into the stock.

“China is a near-term headwind, but not a structural one,” said Harrington. “GEHC has been in China for 40 years. They know how to navigate regulatory shifts. The long-term demand for imaging in China’s aging population is undeniable.”

The spin-off itself is now old news, but the transition is complete. GEHC had its own standalone board, CEO Peter Arduini, and a streamlined balance sheet. For investors who missed the IPO pop, RBC is saying: the real story is just starting.

What This Means for Your Portfolio

If you’re a growth investor chasing triple-digit returns, GEHC probably isn’t your jam. But if you’re looking for a compound-er — a business with pricing power, recurring revenue, and demographic tailwinds — this is the kind of stock that can anchor a portfolio for a decade.

RBC’s initiation is a shot across the bow. And when a top-tier bank starts coverage with a bullish call, the rest of Wall Street tends to follow. Already, 17 analysts cover GEHC, with 10 Buys, 7 Holds, and 0 Sells. That consensus could shift if RBC’s arguments catch fire.

One final thought: healthcare is notoriously lumpy. Hospital system budgets don’t always cooperate. But the secular trends — more scans, earlier detection, AI-assisted workflows — are powerful. GE HealthCare is the biggest pure-play bet on those trends. RBC is betting the house.

And as the company keeps beating estimates, that bet looks smarter by the day.